Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prelude Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prelude Therapeutics's regulatory disclosures and financial reporting.
Prelude Therapeutics has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq notified the company on September 18, 2025 that its common stock once again meets the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2).
This resolves the earlier deficiency notice received in March 2025 and closes the matter, removing the immediate risk of non-compliance with Nasdaq’s continued listing standards for the company’s common stock.
Prelude Therapeutics reported continued operating losses while advancing multiple oncology programs and managing liquidity constraints. For the six months ended June 30, 2025, the company recorded a $63.3 million net loss and had an accumulated deficit of $646.9 million. At June 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $77.3 million, but management states these funds are insufficient to cover at least the next twelve months absent additional financing, and substantial doubt exists about the company’s ability to continue as a going concern.
Operationally, R&D and G&A decreased year-over-year to $54.6 million and $12.2 million for the six months, respectively, as clinical expenses and stock-based compensation moderated. Key program milestones include ongoing Phase 1/2 activity for SMARCA2 degraders (PRT3789 and oral PRT7732) and collaborations with AbCellera and Merck. The company also received a Nasdaq bid price deficiency notice with an initial compliance period through September 23, 2025, and maintains a $400 million shelf registration and a $75 million sales agreement capacity that could support future financing.
Prelude Therapeutics furnished a press release disclosing its financial results for the three months ended June 30, 2025, which is attached to this report as Exhibit 99.1. Management also prepared investor presentation materials intended for use in investor presentations and attached those materials as Exhibit 99.2. The filing notes an interactive data file is included as Exhibit 104.
The report emphasizes that the press release and presentation are being furnished, not filed, and therefore are not incorporated by reference into the company’s other securities filings. The 8-K itself does not include the underlying financial figures in its body; readers must review Exhibit 99.1 for the detailed results. The form is signed on the company’s behalf by Bryant Lim, Chief Legal Officer, Corporate Secretary, and Chief Financial Officer.